Baseline characteristics of the patients randomised
| Tenecteplase 0.25 mg/kg (n=43) | Tenecteplase 0.32 mg/kg (n=43) | |
| Age, years | 68.3 (13.1) | 67.1 (11.5) |
| Male sex | 25 (58.1%) | 31 (72.1%) |
| NIHSS score at randomisation | 11 (8–15) | 9 (6–13) |
| Stroke aetiology | ||
| Cardioembolism | 15 (34.9%) | 7 (16.3%) |
| Large artery atherosclerosis | 20 (46.5%) | 28 (65.2%) |
| Undetermined aetiology | 8 (18.6%) | 8 (18.6%) |
| Medical history | ||
| Atrial fibrillation | 14 (32.6%) | 4 (9.3%) |
| Hypertension | 27 (62.8%) | 29 (67.4%) |
| Diabetes | 12 (27.9%) | 16 (37.2%) |
| Smoking | 15 (34.9%) | 25 (58.1%) |
| Ischaemic stroke or transient ischaemic attack | 6 (14.0%) | 5 (11.6%) |
| TLSW to randomisation | ||
| 4.5–12 hours | 25 (58.1%) | 26 (60.5%) |
| 12- 24 hours | 18 (41.9%) | 17 (39.5%) |
| Witnessed stroke | 21 (48.8%) | 28 (65.1%) |
| Transferred to catheter lab | 17 (39.5%) | 18 (41.9%) |
| Underwent endovascular treatment | 17 (39.5%) | 17 (39.5%) |
| TLSW to hospital arrival, min | 497 (310–815) | 513 (394–632) |
| TLSW to initiation of intravenous therapy, min | 645 (481–973) | 674 (516–808) |
| Time from hospital arrival to initiation of intravenous therapy, min | 130 (99–159) | 140 (111–217) |
| Time from initiation of intravenous thrombolysis to initial angiographic assessment, min* | 69.0 (45.0–94.5) | 62.5 (41.8–93.3) |
| Site of artery occlusion or severe stenosis | ||
| Extracranial segment of intracranial carotid artery | 3 (7.0%) | 6 (14.0%) |
| Intracranial segment of intracranial carotid artery | 3 (7.0%) | 4 (9.3%) |
| First segment of middle cerebral artery | 25 (58.1%) | 15 (34.9%) |
| Second segment of middle cerebral artery | 9 (20.9%) | 11 (25.6%) |
| Anterior cerebral artery | 3 (7.0%) | 6 (14.0%) |
| Tandem occlusion | 0 (0.0%) | 1 (2.3%) |
| Vessel severe stenosis at baseline | 8 (18.6%) | 5 (11.6%) |
| Hypoperfusion lesion volume at baseline, mL | 77 (50–114) | 76 (46–120) |
| Ischaemic core volume at baseline, mL | 8 (4–15) | 8 (4–19) |
Data are mean (SD), n (%), median (IQR).
*Tenecteplase 0.25 mg/kg: n=17; tenecteplase 0.32 mg/kg: n=18.
IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale; SD, standard deviation; TLSW, time from last seen well.